Staphylococcus hominis A9 and Eczema: Why a Safety Trial Was Not Proof of Clearance

November 9, 2026

AI-generated illustration: Skincare jar beside a dry elbow

Dr. Arsy Editorial Team · November 9, 2026

Can a skin bacterium be developed into an eczema treatment? An early trial of Staphylococcus hominis A9 explored that question in 54 adults. It met its primary safety endpoint and changed bacterial measures, but overall eczema severity was not significantly different across all treated participants. ^[4]

The question behind the study

People with atopic dermatitis can have an altered community of skin microbes, and S. aureus is often associated with affected skin. Researchers isolated a different organism, S. hominis A9, from healthy skin and investigated whether it could act against certain S. aureus strains. Laboratory and mouse findings provided a rationale for a human trial; they were not themselves evidence of a treatment effect in people. ^[4][11][12]

The phase 1 study was randomized and double-blinded. Adults with atopic dermatitis and S. aureus-positive skin received the investigational preparation or vehicle on the forearm for one week. Its primary endpoint was safety. Meeting that endpoint supports further study under the trial conditions; it cannot establish long-term safety or approval for everyday consumer use. ^[4]

A bacterial outcome and a skin outcome are different

The researchers observed a significant decrease in S. aureus and an increase in detectable ShA9 DNA as secondary outcomes. Across all treated participants, however, eczema severity was not significantly different. A later, post-hoc analysis suggested improvement in a subset whose bacterial strains were directly susceptible to ShA9. Because that analysis selected a subgroup after examining the data, it is a hypothesis to test again, not proof of reliable eczema clearance. ^[4]

The authors reported relevant financial relationships: two researchers were inventors of related technology, and one reported company equity. Disclosures do not by themselves invalidate results, but they help readers assess a study alongside its design and limitations. ^[4]

Why comparators matter

Other microbiome approaches have followed different paths. Early open-label Roseomonas studies encouraged investigation, but the later FB-401 trial did not show superiority over placebo. B244 studied a different organism and itch endpoint. Two endolysin trials tested proteins rather than applying a live bacterium. A result from one approach cannot establish the result of another. ^{[1][2][3][5][6][7]}

Researchers also examine bacterial lysates, fragrance compounds, inactivated microbial extracts and other topical or systemic therapies. These are distinct interventions; a change in DNA, bacterial culture, skin-barrier measures or symptom scores answers a different question in each study. ^{[8][9][10][14][15][16][17][18]}

Practical meaning for eczema care

Do not put cultured bacteria or untested homemade preparations on damaged skin. If a rash becomes painful, rapidly worsens, develops pus or is accompanied by fever, seek medical care. People with eczema can be colonized with bacteria without requiring antibiotics; a clinician interprets symptoms and any swab together. ^[12][13]

Discuss ongoing itch, sleep loss and medication concerns with a dermatologist or pediatric clinician. Established care uses age-appropriate moisturizing and, when needed, prescribed treatment; it is not replaced by this experimental one-week study. ^[19][20]

Read the wider evidence in context

Skin-microbiome research includes studies of live organisms, inactive bacterial material, proteins targeting bacteria, and ordinary skin-care products. Clinical scores, itch reports, skin barrier tests and bacterial measures do not answer the same question. Guidelines support individualized eczema care and moisturization; studies of other formulas cannot be transferred to a different product. ^{[11][12][13][14][15][16][17][18][19][20]}

Dr. Arsy #003 in a daily routine

Explore Dr. Arsy™ Hydration Recovery Moisturizer #003, 4 oz, a fragrance-free moisturizer for dry, sensitive and eczema-prone skin. The studies discussed here did not test #003 and do not show that it alters the microbiome, treats eczema or treats infection. For babies, ask the child's clinician before choosing skin-care products.

Research and clinical references

Educational information; not a diagnosis or individual medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes